JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Gesloten

73.59 -1.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

73.52

Max

73.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-923M

2.5B

Verkoop

1B

15B

K/W

Sectorgemiddelde

27.832

34.393

Dividendrendement

2.12

Winstmarge

16.947

Werknemers

94,300

EBITDA

-18M

5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+24.72% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.12%

2.54%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

5.1B

231B

Vorige openingsprijs

74.9

Vorige sluitingsprijs

73.59

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

AstraZeneca PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 08:08 UTC

Winsten

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 jul 2025, 06:46 UTC

Winsten

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8 aug 2025, 10:51 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 aug 2025, 11:10 UTC

Populaire aandelen

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 jul 2025, 11:02 UTC

Winsten

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 jul 2025, 11:02 UTC

Winsten

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 jul 2025, 11:01 UTC

Winsten

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 jul 2025, 11:00 UTC

Winsten

AstraZeneca Results: H1 and Q2 2025

29 jul 2025, 08:00 UTC

Marktinformatie
Winsten

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 jul 2025, 07:53 UTC

Marktinformatie
Winsten

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 jul 2025, 07:26 UTC

Marktinformatie
Winsten

AstraZeneca Shares Look Undervalued -- Market Talk

29 jul 2025, 06:03 UTC

Winsten

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 jul 2025, 06:03 UTC

Winsten

AstraZeneca 2Q Total Revenue $14.46B

29 jul 2025, 06:03 UTC

Winsten

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 jul 2025, 06:03 UTC

Winsten

AstraZeneca 2Q Core EPS $2.17

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 jul 2025, 06:02 UTC

Winsten

AstraZeneca Backs 2025 View

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Rev $14.46B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Adj EPS $2.17

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Net Pft $2.45B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q Oper Pft $3.51B

29 jul 2025, 06:00 UTC

Winsten

AstraZeneca PLC 2Q EPS $1.57

28 jul 2025, 10:51 UTC

Marktinformatie

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 jul 2025, 10:19 UTC

Marktinformatie

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 jul 2025, 09:34 UTC

Populaire aandelen

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 jul 2025, 10:59 UTC

Marktinformatie

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Populaire aandelen

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

Peer Vergelijking

Prijswijziging

AstraZeneca PLC ADR Prognose

Koersdoel

By TipRanks

24.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 93 USD  24.72%

Hoogste 97 USD

Laagste 85 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 69.55Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.